Dopaminergic structure-activity relationships of 2-aminoindans and cardiovascular action and dopaminergic activity of 4-hydroxy, 5-methyl, 2-di-n-propylaminoindan (RD-211).

doi:10.1016/s0022-3565(25)22981-0

Paper

Dopaminergic structure-activity relationships of 2-aminoindans and cardiovascular action and dopaminergic activity of 4-hydroxy, 5-methyl, 2-di-n-propylaminoindan (RD-211).

Published Feb 1, 1990 · Shengxing Ma, J. P. Long, J. Flynn

The Journal of pharmacology and experimental therapeutics

Q2 SJR score

2

Citations

0

Influential Citations

Full textSemantic Scholar

Abstract

Abstract hidden due to publisher request; this does not indicate any issues with the research. Click the full text link above to read the abstract and view the original source.

Non-RCT

Animal Study

Study Snapshot

RD-211, a 4-hydroxy-5-methyl-di-n-propyl-2-aminoindan derivative, inhibits heart rate and mean arterial pressure in cats when stimulated by cardioaccelerator nerves, but is inactive at alpha 2-adrenoceptors.

PopulationOlder adults (50-71 years)

Sample size24

MethodsObservational

OutcomesBody Mass Index projections

ResultsSocial networks mitigate obesity in older groups.

Sign up to use Study Snapshot

Consensus is limited without an account. Create an account or sign in to get more searches and use the Study Snapshot.

Create an account

Paper

Dopaminergic structure-activity relationships of 2-aminoindans and cardiovascular action and dopaminergic activity of 4-hydroxy, 5-methyl, 2-di-n-propylaminoindan (RD-211).

Sign up to use Study Snapshot

References

Citations

Recent advances towards the discovery of dopamine receptor ligands

Recent advances in therapeutic agents targeting dopamine receptors D1, D2, D3, and D5 show promise for treating neurological and psychiatric disorders.

Chapter 11 – Aminoindane Analogues

Aminoindane analogues show potential as novel psychoactive substances, but currently play a minor role in recreational use and their toxicity remains uncertain.